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Summary Since it has been shown that pregnancy protects the mammary gland from chemically induced
carcinogenesis, this study was designed with the dual purpose of determining whether treatment of young
virgin rats with the placental hormone chorionic gonadotropin (hCG) mimics pregnancy-induced changes in
the tumourigenic response of the mammary gland and also whether the effect induced by both pregnancy and
hormonal treatments was transitory, or a more permanent one, exerting the same effect when the period of
time between delivery or termination of treatment and exposure to the carcinogen is lengthened. Virgin
Sprague-Dawley rats were utilised in two experimental protocols. For protocol I, 50 day-old rats were either
mated (Group II), or started receiving a daily intraperitoneal injection of 100 IU hCG (Group III) at age 50.
Age-matched untreated virgin rats were used as controls (Group I). Twenty-one days after either delivery or
termination of treatment all the animals received an intragastric dose of 8 mg DMBA/100 gbw. For the second
protocol, 50 day-old virgin rats were also mated (Group V) or were treated with hCG for 21 days (Group VI);
the resting period between delivery or termination of treatment was lengthened to 63 days, at which time they
received a dose of DMBA. Age-matched controls (Group IV) received DMBA only. Tumourigenesis was
evaluated 24 weeks post-carcinogen administration in all the groups. Pregnancy and hCG followed by the
21-day resting period significantly depressed mammary carcinogenesis to 11% and 6% respectively, compared
with 63% in control animals. When the resting period was prolonged to 63 days there was also a significant
depression in adenocarcinoma incidence to 9% in pregnancy (Group V) and 7% in hCG treated (Group VI)
animals respectively, vs 18% in control animals (Group IV) in which it was observed that tumour incidence
was also reduced as a consequence of aging at the time of exposure to the carcinogen. These results clearly
indicate that hCG is as efficient as pregnancy and significantly reduces mammary carcinogenesis, and that the
protective effect of both pregnancy and hCG treatment is long-lasting and both are more efficient than aging
in reducing mammary carcinogenesis.
Epidemiologic data have shown that a single early full-term
pregnancy reduces the lifetime risk of developing breast
cancer (MacMahon et al., 1973; Russo & Russo, 1987).
Experimental data have shown that pregnancy also protects
the mammary gland from chemically induced carcinogenesis
(Russo & Russo, 1987; Russo et al., 1982). Therefore, preg-
nancy can be considered the most physiologic and efficient
means of protecting the breast from neoplastic transforma-
tion. The goal of protecting the mammary gland by mimick-
ing pregnancy in virgin rats by exogenous treatment could be
accomplished by using hormones (Russo et al., 1989a,b). We
have designed studies for determining whether this protection
could be mimicked by treatment of virgin rats with the
placental hormone chorionic gonadotropin (hCG), with the
objective of aiming at inhibiting tumour initiation at the
same level or better than pregnancy. We have already
demonstrated that hCG treatment produces a dose-
dependent inhibition ofmammary carcinomas induced by the
chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA)
(Russo, 1983; Russo et al., 1990a). We have also demon-
strated that hCG significantly inhibits tumour progression
(Russo et al., 1990a).
We designed this study with a dual purpose: (1) to com-
pare the efficiency of full-term pregnancy without lactation
with that of hCG treatment in inhibiting mammary carcino-
genesis, and (2) to determine whether the protective effect of
pregnancy or hormonal treatment on mammary carcinogenesis
was a permanent one or whether it was ameliorated or lost as
the time between the termination of either pregnancy or
treatment and the time of exposure to the carcinogen
lengthened.
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Materials and methods
Outbred virgin Sprague-Dawley rats were purchased from
Harlan Sprague-Dawley (Indianapolis, IN). The animals were
housed four to a cage and were maintained at a temperature
of 24 ± 1'C with a 12 h darkness and 12 h light cycle. The
animals received water and food ad libitum. When they
reached the age of 50 days, they were divided into two
experimental protocols (Figure 1).
In protocol 1, 50 day-old animals were divided into
Groups I, II and III. Group I consisted of virgin females
receiving an intragastric (ig) dose of 7,12-dimethyl-
benza(a)anthracene (DMBA) (Eastman Organic Chemicals,
Rochester, NY) per 100 g of body weight (gbw) when they
reached the age of 92 days (Figure 1). Group II animals were
mated with 80 day-old Sprague Dawley males. The animals
were housed three to a cage, one male and two females. The
morning in which a vaginal plug or sperms were found in the
vaginal smear was considered day 1 of pregnancy. Pregnant
females were separated one to a cage and allowed to deliver
their pups. The number of litters delivered was counted and
the pups were removed immediately upon delivery. Group III
animals consisted of 50 day-old virgin females which were
treated with an intraperitoneal injection of 100 IU hCG
(Sigma Chemical Co., St Louis, MO) for 21 days. This dose
was selected based upon previous results which showed that
it induces the maximal protection from mammary carcino-
genesis (Russo et al., 1990a). Twenty-one days after delivery
in animals of Group II or after the last injection for animals
of Group III, respectively, the animals received an ig dose of
8 mg of DMBA/100 gbw. DMBA was dissolved in corn oil
heated in a water bath at 100'C for 15 min.
For protocol 2, 3 groups of animals, Group IV, controls,
Group V, animals mated at age 50, as described for Group II
and Group VI, virgin animals treated with 100 IU hCG, as
for group III, received an ig dose of 8 mg DMBA/100 gbw
63 days after delivery or hCG treatment (Groups V and VI,
respectively), when they were 134 days old (Table I, Figure 1).
All the animals were palpated twice a week for detection of
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Figure 1 Schematic representation of the experimental protocol.
Protocol eomprises Groups I, and Protocol 2 comprises
Groups IV, V and VI. Pregnancy (Preg); resting period (RP);
human chorionic gonadotropin (hCG) 100 IU/day for 21 days;
7,12-dimethylbenz(a)anthracene (DMBA).
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Figure 2 Tumour incidence (ordinate): Percentage of animals
with tumours (in tens); 7,12-dimethylbenz(a)anthracene (DMBA);
Pregnancy (P) + resting period (RP); human chorionic gonado-
tropin (hCG). - DMBA, [mm P + 21d-RP + DMBA, OM
hCG + 21d-RP + DMBA, M DMBA, M P + 63d-
RP + DMBA, = hCG + 63d-RP + DMBA.
tumour development. The date of tumour appearance and
tumour location were recorded. The final tumourigenic re-
sponse was evaluated 24 weeks after DMBA administration
(Figure 1).
All tumours and the mammary glands were dissected from
the skin and processed as described elsewhere (Russo et al.,
1989c). Sections of tumours were stained with haematoxylin
and eosin. Tumours were classified by applying criteria pub-
lished elsewhere (Russo et al., 1990b,e Russo et al., 1989e).
The proportions of DMBA-induced tumours and DMBA-
induced adenocarcinomas were analysed by the chi-square
test and Fisher's exact probability two-tail test (Zar, 1984).
Results
Mammary tumours were observed in all groups of DMBA
inoculated animals, although their incidence was significantly
depressed by pregnancy, hCG treatment and aging prior to
exposure to the carcinogen (Table I). Maximal tumourigenic
response was exhibited by control virgin rats (Group I)
inoculated with the carcinogen when they were 92 days-old
(Table I, Figures 2 and 3).
A significant reduction in tumour incidence was observed
in animals in which pregnancy was completed 21 days prior
to DMBA treatment (Group II). Age-matched hCG-treated
rats (Group III) also developed significantly fewer tumours
(Table I, Figures 2 and 3). When tumours were histologically
classified it was found that the predominant tumour types
were adenocarcinomas and fibroadenomas, both of which
were present in both control and hCG treated rats, whereas
parous animals (Group II) developed only adenocarcinomas,
which were present at the same percentage as in hCG-treated
animals (Table I, Figures 2 and 3).
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Figure 3 Adenocarcinoma incidence (ordinate): Percentage of
animals developing mammary adenocarcinomas (in tens).
Legends as per Figure 2. - DMBA, EIll P + 21d-
RP + DMBA, hCG + 21d-RP + DMBA, DMBA,
M P + 63d-RP + DMBA, LD hCG + 63d-RP + DMBA.
In animals of protocol 2, in which the resting period after
delivery or termination of hormonal treatment was prolonged
to 63 days, it was observed that both experimental groups
exhibited a significant diminution in both tumour and
adenocarcinoma incidence in comparison with the age-
matched control groups. As it was observed in animals of
protocol 1, the total number of tumours in parous animals
(Group V) was lower than in hCG treated animals (Group
VI). The incidence of adenocarcinomas was significantly
reduced by both pregnancy and hCG treatment in com-
Table I Effect of hCGI on DMBA-induced mammary carcinogenesis
Twnours Adenocarcinoma
Total No. Total no. No. TI No. Total No. No. Latency period
Group Treatment No. An. An. % twnours An.b An. % AdCac AdCaIAn/d in days
Protocol I
I ---/DMBA' 80 49 61.3' 101 1.26 35 48.309 73 0.91 55-191
II Pregnancy/DMBA 18 1 5.6f 1 0.06 1 5.69 1 0.06 91
III hCG(100 IU)/DMBA 65 19 29.2f 27 0.41 4 6.159 4 0.06 90-195
Protocol 2
IV ---/DMBA 27 12 44.4f 18 0.67 5 18.52g 5 0.18 52-153
V Pregnancy/DMBA 21 3 14.28' 4 0.19 2 9.529 2 0.09 52-210
VI hCG(100 IU)/DMBA 27 7 25.92f 7 0.25 2 7.409 2 0.07 52-210
ahCG - Human chorionic gonadotropin. bNumber of tumours. cAdCa - Adenocarcinoma. dNumber of adenocarcinomas per
animal per total number ofanimals at risk. 'DMBA - 7,12-dimethylbenz(a)anthracene, 8 mg/100 g body weight. fTumour incidence
chi-square with d.f. = 3, value 22.4118 and sample size 254 probability is P = 5.35 x 10-5. gCarcinoma incidence chi-square with
d.f. = 3, value 31.6775 and sample size 254 probability is P = 6.12 x 10-7.
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parison with the incidence in age-matched controls (Group
IV), but there was no difference in adenocarcinoma incidence
between parous and hCG treated animals (Table I, Figures 2
and 3). The protection induced by hCG and pregnancy was
similar in animals receiving the carcinogen at different times
(Table I, Figures 2 and 3).
Control animals of Group III developed fewer tumours
and adenocarcinomas than control animals in Group I,
which was due to aging of these animals prior to exposure to
the carcinogen (Table I, Figures 2 and 3).
As it has been previously demonstrated (Russo et al., 1982)
and confirmed in these results, aging per se significantly
reduced mammary carcinogenesis, nevertheless pregnancy
and hCG treatment were still more effective in reducing both
tumour and adenocarcinoma incidence. Although the protec-
tion induced by both pregnancy and hCG was longlasting,
there appeared to exist a threshold of susceptibility to car-
cinogenesis which was not modified by pregnancy, hormonal
treatment, variations and length of time after completion of
pregnancy or treatment or aging, since exposure to the car-
cinogen always succeeded in inducing at least one carcinoma
per group (Table I).
Discussion
Results presented here demonstrate that both pregnancy and
hCG treatment have a similarly protective effect on DMBA-
induced mammary carcinogenesis and that this protection is
longlasting, since the same reduction in carcinoma incidence
is observed when the carcinogen is administered after either
21 or 63 days post-delivery or termination of the hormonal
treatment respectively.
Our studies on the pathogenesis and prevention of
chemically-induced mammary carcinogenesis have allowed us
to conclude that the degree of differentiation of the mam-
mary gland is one of the most important biological charac-
teristics in determining its overall tumourigenic response
(Russo & Russo, 1987; Russo et al., 1982, 1990d). Maximal
susceptibility to DMBA-initiated neoplastic transformation is
exhibited by mammary glands of young nulliparous females,
which are characterised by the presence of undifferentiated
terminal ductal structures or TEBs exhibiting a high rate of
cell proliferation. The minimal susceptibility to chemically-
induced carcinogenesis exhibited by the mammary gland of
parous animals is attributed to its full differentiation (Russo
& Russo, 1980, 1987; Russo et al., 1982). Differentiation
induced by pregnancy eliminates the targets of the car-
cinogen, sinced the parous rat mammary gland exhibits a
reduction in number or total absence of TEBs and reduction
in the proliferative activity of the mammary epithelium, in
which the cells shift from a proliferative to a resting or Go
compartment (Russo & Russo, 1980).
Based upon the observed powerful influence of differenti-
ation in inhibiting tumour initiation, our research has been
geared to determine what hormone or hormone combinations
can mimic pregnancy in stimulating gland differentiation to a
degree in which it is protected from chemical carcinogenesis
(Russo et al., 1982; 1989a,b; Russo & Russo, 1987). In
comparative studies we have tested the effect of the contra-
ceptive agents norethynodrel-mestranol (Russo et al., 1989a)
and medroxyprogesterone (MPA) (Russo et al., 1989b) a
combined oral and an injectable progestagenic contraceptive,
respectively, and the placental hormone chorionic gonado-
tropin (hCG) (Russo et al., 1990a). These hormones have
been used in identical protocols for treating young virgin rats
for 21 days, the length of time of pregnancy, and stopped 21
days prior to carcinogen administration (Russo et al.,
1989a,b, 1990a,c,d). Treatment with various doses of hCG
showed a dose-related protective effect (Russo, 1983; Russo
et al., 1990a), an effect similar to that of norethynodrel-
mestranol (Russo et al., 1989a), whereas MPA reduced
tumour incidence only with the dose clinically used for con-
traception, but a higher dose resulted in greater tumourigenic
response (Russo et al., 1989b). Chorionic gonadotropin, like
pregnancy, induces full differentiation of the mammary
gland, morphologically manifested as a reduction in the
number of TEBs, increase in lobular formations and depres-
sion of DNA synthesis (Russo et al., 1990c).
The use of hormones for inhibiting mammary car-
cinogenesis has been explored by several authors (Dao et al.,
1960; Dao & Sutherland, 1959; Grubbs et al., 1983a,b, 1986;
Huggins et al., 1961, 1962; McCormick & Moon, 1965, 1973;
Welsch, 1985). Among the hormones tested for this purpose
have been treatment with oestrogen and progesterone at
different doses (Grubbs et al., 1983b; McCormick et al.,
1965), although hormone deprivation through ovariectomy
or administration of the anti-oestrogen tamoxifen also inhibits
mammary carcinogenesis (Welsch, 1985). In general all these
protocols produce protection, although to a different degree.
However, none of those treatments can be considered to be a
physiologic means for breast cancer prevention, since they
modify the reproductive and endocrinologic profile of the
animal. The protocols we use for preventing mammary car-
cinogenesis are unique in the sense that treatments are
administered for the same length of pregnancy and they are
terminated 21 or more days prior to exposure to the car-
cinogen, thus testing their effect as permanent modifiers of
the mammary gland architecture and cell kinetic properties
(Russo et al., 1989a,b, 1990a).
In the present work, the fact that either pregnancy or hCG
treatment sufficed to induce a lasting protective effect on the
initiation ofmammary carcinomas, which was still evident by
63 days post treatment supports the concept that permanent
changes have occurred in the mammary gland and are opera-
tional in protecting the mammary gland from chemical car-
cinogenesis, thus allowing to rule out that modifications in
circulating hormonal levels (Ciocca et al., 1982), or an
immunologic response elicited by the foetus (Sinha et al.,
1988) are responsible of the protective effect of pregnancy.
HCG at the doses utilised induces ovulation and maintains
the corpus luteum in the ovary (Amsterdam et al., 1975;
Rajaniemii et al., 1985; Uilenbrock et al., 1985; Wide et al.,
1980), which in turn secretes oestrogens and progesterone,
both of which stimulate gland differentiation by mechanisms
similar to those operational during pregnancy. The fact that
hCG is not tumourigenic, does not induce alterations in body
weight or in the weight of endocrine organs such as pituitary
gland and adrenal glands, and that after hormone with-
drawal the animals return to a normal oestrous cycle (Russo
et al., 1990c,d), indicate that although pregnancy seems to be
the most physiologic mechanism for preventing the initiation
of mammary carcinogenesis, hCG adequately mimics the
effect of pregnancy, making the use of this protocol for
cancer prevention an appealing idea that needs further ex-
ploration.
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